Novartis sells stake in consumer healthcare JV to GSK for $13.0 billion
Novartis will sell its 36.5 percent stake in its consumer healthcare joint venture (JV) to GSK for $13.0 billion, it…
Pharmaceuticals, Biotechnology and Life Sciences
Novartis will sell its 36.5 percent stake in its consumer healthcare joint venture (JV) to GSK for $13.0 billion, it…
Vifor Pharma Group has granted Japanese company Zeria Pharmaceutical exclusive rights to develop and commercialise Veltassa, its sodium-free potassium binder approved…
Bristol-Myers Squibb said on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
GeNeuro’s results from the Phase 2b study of its novel therapeutic treatment of multiple sclerosis (MS) showed a significant, consistent positive…
Portola will need to provide further clarification to the European Medicines Agency (EMA) for making betrixaban available for the prevention the VTE…
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion…
Novartis could have the first therapy which could delay disability progression secondary progressive multiple sclerosis (SPMS) if it gets the…
GlaxoSmithKline got the approval for shingles prevention, and post-herpetic neuralgia (PHN) vaccine Shingrix, in Europe, while in Japan it was registered…
The Japanese Ministry of Health, Labour and Welfare has approved Novo Nordisk’s treatment for type 2 diabetes adult patients, new…
CARB-X is partnering with Shionogi of Osaka, Japan, to support the development of a novel β-lactam antibiotic with potent activity…